Judy Mak

TL;DR: It is proposed that blocking NRP1 function inhibits vascular remodeling, rendering vessels more susceptible to anti-VEGF therapy, and generated two monoclonal antibodies that bind to the Sema- and VEGF-binding domains of N RP1.

TL;DR: The results demonstrate that Nrp2, which was originally identified as an axon-guidance receptor, is an attractive target for modulating metastasis and reduces tumoral lymphangiogenesis and, importantly, functional lymphatics associated with tumors.

TL;DR: If neuropilin-2 and the growth factor VEGF-C do not come together, lymphatic vessels don’t branch apart and the immune system shuts down.

TL;DR: NRP1 is characterized as a valid anti‐angiogenic target in malignancy, and as a potential direct anti‐tumour target in a subset of cancers, and a role for NRP1 in physiological, VEGF‐mediated angiogenesis is confirmed.

TL;DR: neutralization of CSF1 and IL34 in adult mice identified that they play important roles in macrophage differentiation, specifically in steady-state microglia, Langerhans cells, and kidney macrophages, and therapeutic intervention targeting IL34 and/orCSF1 may provide an effective treatment in macophage-driven immune-pathologies.